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Abstract Age-related macular degeneration (AMD) is an
ophthalmologic disease which usually affects older adults
and represents the leading cause of legal blindness in
Europe and the United States of America. The pathogenesis
of AMD is complex and, nowadays, the treatments are
targeting more the late form of the disease. Age and genetic
make-up are the most important risk factors identified to
date. There are undoubtedly environmental and other risk
factors involved and the adverse effect of smoking is well
established. New treatments for AMD have emerged with
improved prognostic outcome. This remarkable advances in
our understanding of the genetic and biological foundations
of this disease were derived from a recent convergence of
scientific and clinical data. In the near future we will have
several therapeutic options for treatment of AMD at
different stages and therefore personalising more and more
the treatment.
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Introduction
Age-related macular degeneration (AMD) is an ophthalmo-
logic disease which usually affects older adults and results
in a loss of vision in the center of the visual field, because
of damage to the central retina, called the macula. It occurs
in a “dry” (non-neovascular) and a “wet” (neovascular)
form, the wet form being more sight-threatening. AMD can
make it difficult or impossible to read or recognise faces,
although enough peripheral vision remains to allow other
activities of daily life. AMD starts with characteristic
yellow deposits (drusen) in the macula between the retinal
pigment epithelium and the underlying choroid. At this
early stage of the disease experts are speaking of age-
related maculopathy rather then AMD. If the drusen are
becoming more numerous, geographic atrophy or marked
pigmentary changes are occurring the term AMD is applied.
From good vision in earlier stages the visual acuity will
drop in later stages with preserved peripheral vision.
AMD is the leading cause of legal blindness in Europe
[1, 2] and the United States of America. Worldwide about
30 million people are affected by the disease. Especially,
the prevalence and incidence of AMD is increasing in
individuals older than 50 years old. According to the
demographic evolution of the population the amount of
people with AMD will grow even more. The pathogenesis
of AMD is complex and, nowadays, the treatments are
targeting more the late form of the disease. Age and genetic
make-up are the most important risk factors identified to
date. There are undoubtedly environmental and other risk
factors involved and the adverse effect of smoking is well
established.
Predictive diagnostics and risk factors for AMD
The gold standart for AMD diagnostics is primarily a
fundus examination of the macula (central area of the
retina). Additionally, fluorescein angiography (FLA) and
optical coherence tomography (OCT) are used to assess the
disease. FLA is a technique for examining the circulation of
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the retina using the dye tracing method. It involves
injection of sodium fluorescein into the systemic circula-
tion, and then an angiogram is obtained by photographing
the fluorescence emitted after illumination of the retina.
OCT is an optical signal acquisition and processing method
using the interferometric technique and producing scans of
the posterior part of the eye. These three investigations are
helping the ophthalmologist to differentiate between the
two main forms of AMD, dry (non-neovascular) and wet
(neovascular). Follow-up controls will then characterise the
disease course, help to predict the further evolution and
imply an adjusted management of the patient.
Nowadays the etiology of AMD is believed to be an
interaction of environmental impacts and genetic factors.
Newest investigations show that AMD is probably caused
in two-third of the cases by genetic predisposition.
Ocular and systemic risk factors
Iris color, hair color, and skin sun sensitivity are not
associated with the development of late forms of AMD [3].
Other ocular factors like refraction and cataract seem not to
be a risk factor for AMD. Only a small number of
published studies investigated the development or progres-
sion of AMD following cataract surgery. The results were
inconsistent, nevertheless a promoting influence of cataract
surgery on the progression of early age-related macular
degeneration can be assumed [4].
Some studies showed a correlation between cardiovas-
cular risk factors and progression of AMD, but the results
were not consistent. In histological examinations accumu-
lation of lipids with age appears to be greater in the central
fundus than in the peripheral region, indicating that lesions
in AMD and Bruch’s membrane lipid deposits with age
share a common spatial distribution, but there is no clear
correlation between blood cholesterol and higher risk for
AMD [5]. Regarding the association among hyperglycae-
mia, diabetes status, and age-related maculopathy large
studies proved that diabetes is not related to early age-
related maculopathy or dry forms of AMD [6].
External risk factors
AMD involves a progressive impairment of the outer
layers, especially photoreceptors, in the centre of the retina.
Experimental studies have demonstrated that bright light
preferentially damages precisely the region that degenerates
in AMD. Although the physiological pigments melanin,
lutein and zeaxanthin are acting as photoprotectant in the
macula, solar radiation is responsible for some of the
deteriorative changes that lead to AMD. In the human
retina, documented lesions from solar radiation range from
the acute effects of sun-gazing to injuries resulting from
prolonged periods of exposure in brightly illuminated
environments. The damage occurs in the same region that
degenerates in AMD [7]. Nevertheless, it is difficult to
prove the effect of light promoted AMD (Figs. 1, 2 and 3).
In a pooled three-continent study there is a growing
body of evidence indicating that smoking is related to an
increased risk of incident AMD and is the leading external
risk factor for AMD. Smoking is associated with a two-fold
increased risk of developing AMD. Current smokers were
at higher risk of incident AMD than both past smokers and
those who never smoked [8, 9]. Some studies could even
demonstrate a strong association between the risk of advanced
forms of AMD, both dry and wet, and pack years of cigarette
smoking. There seem to be even an increased risk for AMD in
non-smokers exposed to passive smoking. Stopping smoking
appears to reduce the risk of developing AMD [10, 11].
Smoking reduces the concentration of antioxidant in the
blood and probably also the function of antioxidant enzymes
in the macula. Additionally, Factor H being an important
element of the pathogenesis of AMD shows an age-
dependent increase of the plasma level and a decrease in
smokers [12]. However, the exact mechanism how smoking
is influencing AMD needs still to be elucidated.
Lipofuscin and vascular endothelial growth factor (VEGF)
In the pathogenesis of AMD many mechanism are
discussed. Regarding the two main forms, dry and wet
AMD, the formation of lipofuscin plays an important role
for the non-neovascular form and pro- and antiangiogenic
factors more for the neovascular form. Lipofuscin is
considered one of the ageing pigments, found in the liver,
kidney, heart muscle, adrenals, nerve cells and pigment
epithelium of the eye. It is specifically arranged around the
Fig. 1 82-year old patient with advanced AMD and decreased visual
acuity to hand motions in the right eye. The central area of the retina,
called the macula, is affected by a large scar tissue
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nucleus, and is a type of lipochrome. Lipofuscin accumu-
lation in the retinal pigment epithelium is associated with
various blinding retinal diseases, including AMD. The
major lipofuscin fluorophor A2-E is thought to play the
most important pathogenetic role. It has been shown that
A2-E severely impairs lysosomal function of RPE cells as a
potent inhibitor of the ATP-driven proton pump located in
the lysosomal membrane. Such inhibition of proton
transport to the lysosomal lumen results in an increase of
the lysosomal pH with subsequent inhibition of lysosomal
hydrolases. An essential task of the lysosomal apparatus of
retinal pigment epithelium cells for normal photoreceptor
function is phagocytosis and degradation of membranous
discs shed from photoreceptor outer segments and of
biomolecules from autophagy. When lysosomes of cultured
retinal pigment epithelium cells were experimentally loaded
with A2-E, there was an intracellular accumulation of
exogenously added photoreceptor outer segments. More-
over, the autophagic sequestration of cytoplasmic material
was also markedly reduced after A2-E loading. These data
support the hypothesis that A2-E-induced lysosomal dys-
function contributes to the pathogenesis of AMD [13].
Vascular endothelial growth factor (VEGF) is a chemical
signal produced by cells that stimulates the growth of new
blood vessels. It is part of the system that restores the oxygen
supply to tissues when blood circulation is inadequate.
VEGF’s normal function is to create new blood vessels
during embryonic development, new blood vessels after
injury, muscle following exercise, and to bypass blocked
vessels. When VEGF is overexpressed, it contributes to the
wet form of AMD. VEGF blocking with VEGF-inhibitors
like ranibizumab or bevacizumab has revolutionised the
treatment of neovascular AMD since 2006 [14]. The
treatment is stabilising the disease and visual acuity in
many cases, although repetitive intravitreal applications are
necessary in most of the cases.
Genetics
Age and genetic make-up are the most important risk
factors for AMD identified to date. Over the next decade,
the different genes that are involved in the development of
age-related macular degeneration will be identified [15].
Many studies suggested a genetic implication for AMD.
For example the prevalence of age-related maculopathy
among first-degree relatives of subjects with age-related
maculopathy, particularly with exudative disease, is greater
then among first-degree relatives of subjects without this
disease [16]. Another interesting point is that genetic
susceptibility may play an important role in determining
the onset of disease and therefore a better understanding of
the genetic factors in AMD would contribute to under-
standing the pathogenesis [17]. If those at risk could be
identified it may be possible to modify lifestyle or develop
novel therapies in the presymptomatic stage to prevent
disease or decrease its severity.
Several hereditary retinal dystrophies show similarities
to AMD and these genes are potential candidate suscepti-
bility genes. Particular interest has focused on the ABCR
gene which is responsible for autosomal recessive Stargardt
macular dystrophy. It has been claimed that heterozygotes
for ABCR mutations are predisposed to AMD but the data
are conflicting. Studies of the genes responsible for
autosomal dominant Sorsby fundus dystrophy, Doyne
honeycomb retinal dystrophy, and Best disease have given
negative results. In one large AMD family, linkage has been
reported to markers in 1q25-q31. Recent data suggest that
the ApoE epsilon4 allele may be associated with reduced
risk of AMD [18]. Linkage and association studies have
identified other chromosomal regions that are likely to
Fig. 3 Same eye and patient as in Fig. 1. Fluorescent angiography
(FLA) late phase reveals the large area of the involved tissue in the
macula
Fig. 2 Same eye and patient as in Fig. 1. Optical coherence tomography
(OCT) showing the atrophy of the retina and the subretinal scar tissue
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contain susceptibility loci with strongest evidence found on
chromosome 1q31 and 10q26. Variants in the complement
factor H (CFH) gene have been shown by several indepen-
dent studies to be associated with an increased risk for AMD
in Caucasian populations. Factor H is a member of the
regulators of complement activation family functioning as a
complement control protein. Its main job is to regulate the
alternative pathway of the complement system, ensuring that
the complement system is directed towards pathogens and
does not damage host tissue. The implication of complement
factor H shows that the innate immune system may play a
significant role in AMD pathogenesis. The LOC387715/
HTRA1 locus within 10q26 has been identified as a second
major locus contributing to AMD pathogenesis [19].
It can be argued that age-related macular degeneration is
one of the best characterised complex trait diseases.
Extensive information related to genetic and environmental
risk factors exists, and a number of different biological
pathways are strongly implicated in its aetiology. Along
with recent improvements in high throughput and relatively
inexpensive genetic technologies, we are now in a position
to consider developing a presymptomatic, personalised
approach towards the assessment, management and treat-
ment of this disease. We explore the applicability and
challenges of this approach if it is to become commonplace
for guiding treatment decisions for individuals with pre-
existing disease or for those at high risk of developing it.
Prevention and prophylaxis
Vitamines
Oxidative stress, which refers to cellular damage caused by
reactive oxygen intermediates (ROI), has been implicated in
many disease processes, especially age-related disorders.
ROIs include free radicals, hydrogen peroxide, and singlet
oxygen, and they are often the byproducts of oxygen
metabolism. The retina is particularly susceptible to
oxidative stress because of its high consumption of oxygen,
its high proportion of polyunsaturated fatty acids, and its
exposure to visible light. In vitro studies have consistently
shown that photochemical retinal injury is attributable to
oxidative stress and that the antioxidant vitamins A, C, and
E protect against this type of injury. Furthermore, there is
strong evidence suggesting that lipofuscin is derived, at
least in part, from oxidatively damaged photoreceptor outer
segments and that it is itself a photoreactive substance.
However, the relationships between dietary and serum
levels of the antioxidant vitamins and age-related macular
disease are less clear, although a protective effect of high
plasma concentrations of alpha-tocopherol has been con-
vincingly demonstrated [20]. Macular pigment as men-
tioned before is also believed to limit retinal oxidative
damage by absorbing incoming blue light and/or quenching
ROIs. Many putative risk-factors for AMD have been
linked to a lack of macular pigment, including female
gender, lens density, tobacco use, light iris color, and
reduced visual sensitivity. Moreover, the Eye Disease Case-
Control Study found that high plasma levels of lutein and
zeaxanthin were associated with reduced risk of neo-
vascular AMD. The concept that AMD can be attributed
to cumulative oxidative stress is enticing, but remains
unproven. With a view to reducing oxidative damage, the
effect of nutritional antioxidant supplements on the onset
and natural course of age-related macular disease is
currently being evaluated [21]. Lutein and zeaxanthin are
concentrated at the macula, where they are collectively
known as macular pigment, and where they are believed to
play a major role in protecting retinal tissues against
oxidative stress. Whilst the exact pathogenesis of AMD
remains unknown, the disruption of cellular processes by
oxidative stress may play an important role. Manipulation
of dietary intake of lutein and zeaxanthin has been shown to
change macular pigment concentration, thereby raising
hopes that dietary supplementation with these carotenoids
might prevent, delay, or modify the course of AMD [22].
Lipids are known to accumulate in Bruch’s membrane, an
acellular layer with no known intrinsic mechanisms to
combat lipid peroxidation. In related studies, lipid per-
oxides have been shown to induce neovascularisation by
inducing expression of a cascade of angiogenic cytokines.
Lipid peroxides are biological molecules that have the
potential to incite new vessel growth. The increase in amount
of peroxidised lipids with age, combined with their vaso-
genic potential, suggests that peroxidised lipids may play a
role in the aetiology of age-related macular degeneration,
particularly choroidal neovascularisation [23].
Zinc
Zinc is an essential mineral of very important biologic and
public health importance. Zinc deficiency affects about two
billion people in the developing world and is associated
with many diseases. Zinc has long been recognised as an
essential constituent of various tissues. Many clinical
conditions and dietary factors reduce the absorption or the
biological availability of zinc, and lead to zinc deficiency
which produces structural and functional alterations in
many organ systems. The highest concentration of this
trace element in the human body is measured in the eye,
particularly in the pigment-containing components. The
deficiency of zinc has a dramatic effect on ocular
development especially when it occurs during early prenatal
period [24, 25]. Zinc is required for the structure and
activity of many ocular metalloenzymes and plays a role in
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the metabolic function of several important enzymes in the
chorioretinal complex. Although the exact mechanism of its
molecular and cellular functions are largely unknown the
essentiality of this element in the component of the eye,
including the retina, choroid, cornea and lens, is well
established; it is also well known that zinc deficiency
causes functional impairments in various parts of the eye.
Zinc related toxicities have been shown in human and
animal eyes [26]. A controlled oral intervention study
showed a positive, if limited, treatment effect in AMD.
Because of the possible toxic effects and complications of
oral zinc administration, widespread use of zinc in macular
degeneration is not now warranted.
In 2001 the “Age-Related Eye Disease Study” (AREDS),
one of the biggest studies ever performed in the ophthalmo-
logic field regarding vitamins and micronutrients has been
published [27]. 3640 patients have been involved and
followed for more than 6 years. The goal of the study was
to demonstrate the effect of antioxidative vitamins in high-
doses (vitamine C, Betacarotin, Vitamin E) and the micro-
nutrient zinc (combined with copper) on progression of
AMD. According to the clinical fundus picture patients
have been put into four categories, the first being beginning
and the last advanced AMD. The patients have been
randomised into four groups with group 1 only antioxidative
vitamins, group 2 only zinc (and cupper), group 3 combina-
tion of vitamins and zinc and group 4 placebo. Both, zinc and
antioxidants plus zinc significantly reduced the odds of
developing advanced AMD in the two advanced AMD
categories and the only statistically significant reduction in
rates of at least moderate visual acuity loss occurred in
persons assigned to receive antioxidants plus zinc [27].
Therefore the recommendation was that persons with
intermediate or advanced form of AMD in one eye should
consider taking the AREDS-type supplements. Further
evaluation of nutritional factors, specifically, lutein/zeaxan-
thin and omega-3 fatty acids will be tested in another large
multicenter controlled, randomised trial—the Age-Related
Eye Disease Study 2 (AREDS2) [28]. In an animal model
increasing omega-3-PUFA tissue levels by dietary or genetic
means decreased the avascular area of the retina by increasing
vessel regrowth after injury, thereby reducing the hypoxic
stimulus for neovascularisation. The bioactive omega-3-
PUFA-derived mediators neuroprotectinD1, resolvinD1 and
resolvinE1 also potently protected against neovascularisation.
The protective effect of omega-3-PUFAs and their bioactive
metabolites was mediated, in part, through suppression of
tumour necrosis factor-alpha. These findings indicate that
increasing the sources of omega-3-PUFA or their bioactive
products reduces pathological angiogenesis which could
influence the course of AMD [29]. Omega-3 (n-3) Long-
chain polyunsaturated fatty acids (LCPUFAs) affect processes
implicated in vascular and neural retinal pathogenesis and
thus may influence the risk of developing age-related macular
degeneration (AMD). The 12-y incidence of dry and wet
AMD in participants at moderate-to-high risk of these
outcomes was lowest for those reporting the highest con-
sumption of omega-3 LCPUFAs [30].
Antiinflammatory, antioxidative and other substances
Tyrosinkinase inhibitors
Tyrosinkinase inhibitors are interfering with the signal
transduction of growth hormons. The tyrosinkinase inhibitor
genistein found in a number of plants, with lupin, fava beans,
soybeans, kudzu, and psoralea being the primary food source
acts as antioxidant, similar to many other isoflavones,
counteracting damaging effects of free radicals in tissues.
The isoflavonoid genistein is a natural tyrosinkinase inhibitor
and is very potent in inhibition of endothelial cell proliferation
and in vitro angiogenesis. Moreover, genistein inhibits the
proliferation of various tumour cells. Genistein excretion in
urine of subjects consuming a plant-based diet is in the
micromolar range, which is 30-fold higher than that of
subjects consuming a traditional Western diet. Thus genistein
with tyrosinkinase inhibiting and antioxidant properties may
have important applications in the treatment of solid tumours
and angiogenic diseases [31, 32].
Statins
The statins or HMG-CoA reductase (3-hydroxy-3-methyl-
glutaryl-coenzyme A reductase) inhibitors are a class of
drug used to lower plasma cholesterol level. Inhibition of
HMG-CoA reductase in the liver results in decreased
cholesterol synthesis as well as increased synthesis of
LDL receptors, resulting in an increased clearance of low-
density lipoprotein (LDL) from the bloodstream. It has been
postulated that there is association between increased risk
of neovascular AMD and higher levels of serum cholesterol
[33, 34]. Additionally, statins exhibit action beyond lipid-
lowering activity in the prevention of atherosclerosis.
Researchers hypothesise that statins prevent cardiovascular
disease via four proposed mechanisms (all subjects of a
large body of biomedical research): improving endothelial
function, modulating inflammatory responses, maintaining
plaque stability and preventing thrombus formation [35].
Most of these mechanisms are of interest in the pathogenesis
of AMD. Nevertheless, recent evaluations of the impact of
statin use on the incidence of advanced AMD and its
components, choroidal neovascularisation (wet AMD) and
geographic atrophy (dry AMD), showed that there is no
consistent strong protective effect of statins on the develop-
ment of advanced AMD among patients with bilateral large
drusen [36].
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Cyclooxygenase-inhibitors
Cyclooxygenase (COX) is an enzyme that is responsible for
formation of important biological mediators called prostanoids
like prostaglandins, prostacyclin and thromboxane. Pharma-
cological inhibition of COX can provide relief from the
symptoms of inflammation and pain. Since inflammation is
believed to be a part of the AMD pathogenesis puzzle, COX
inhibitors may have a therapeutic effect. Nepafenacfor for
example is a potent nonsteroidal antiinflammatory drug that
rapidly penetrates the eye following topical ocular adminis-
tration. In the eye, nepafenac is converted to amfenac,
which has unique time-dependent inhibitory properties for
COX-1 and COX-2. Amfenac treatment significantly
reduced retinal prostanoid production and neovascularisa-
tion in an in vitro experiment. Therefore nepafenac appears
to be a promising advancement in the development of
therapies for neovascular eye diseases [37].
COX-inhibitors influence also the proliferation and
differentiation of endothelial cells which could probably
have another effect especially on neovascular AMD. The
results of ongoing studies are still missing.
Complement inhibition
The complement system is a biochemical cascade that helps
the ability of antibodies to clear pathogens from an
organism. It consists of a number of small proteins found
in the blood, generally synthesised by the liver, and
normally circulating as inactive precursors (pro-proteins).
These proteins are binding to specific complement recep-
tors on the cells of the immune system and are triggering
specific cell functions, inflammation, and certain immuno-
regulatory molecules. Since genetic polymorphism has
been found in the complement system in AMD patients,
research has started to focus on complement inhibition.
Especially complement factor 3 (C3) plays a central role in
the activation of complement system. Its activation is
required for both classical and alternative complement
activation pathways and is therefore a classical target for
inhibition of the complement system [38, 39].
Personalised Medicine
Wet AMD treatment
Wet (neovascular) AMD representing a late stage of the
disease is nowadays efficiently treated with anti-VEGF
therapy in most of the cases [40]. This treatment is
performed with an intravitreal injection which often has to
be repeated. The most serious known risk of treatment,
endophthalmitis, although rare, is always a possibility.
Anti-VEGF treatment does not represent a cure of this
chronic disease, but helps to transform the more aggressive
wet AMD into a dry form. Therefore the goal of the
treatment is not healing but stabilisation and prevention of
vision loss but also improvement in best-corrected visual
acuity. Although inhibition of vascular endothelial growth
factor with anti-VEGF has demonstrated efficacy and safety
in the treatment of neovascular AMD, novel and combina-
tion (for example anti-VEGF and photodynamic therapy)
treatments targeting different mechanisms that play a role in
CNV development currently are being investigated. Data
from these clinical trials will increase our knowledge of the
pathogenesis of AMD and likely provide additions to the
treatment armamentarium for improving vision and quality
of life in patients with AMD [41].
Dry AMD treatment
Regarding early stages of AMD and dry AMD there is at the
present time insufficient evidence in the literature to recom-
mend routine nutritional supplementation in healthy adults for
primary prevention of AMD. However, patients with inter-
mediate risk of AMD or advanced AMD in one eye should
consider taking AREDS-type supplements [27]. Obser-
vational studies have also suggested benefit from increased
dietary intake of macular xanthophylls and omega-3 fatty
acids. These are currently being evaluated prospectively in a
randomised controlled clinical trial, the AREDS2 [42].
Concluding remarks and outlook
In summary, AMD is a leading cause of vision loss in people
over the age of 60 with a prevalence that continues to rise.
Although treatments for AMD were once limited, with
disappointing clinical results, new treatments have emerged,
which have improved prognostic outcome [43]. Remarkable
advances in our understanding of the genetic and biological
foundations of this disease were derived from a recent
convergence of scientific and clinical data. Collectively, this
wealth of information has provided a drive for the develop-
ment of powerful tools to accurately diagnose disease risk
and progression and complement-based therapeutics that
will ultimately delay or prevent AMD [44]. In the near
future we will have several therapeutic options for treatment
of AMD at different stages and therefore personalising more
and more the treatment.
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